A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19

PHASE2/PHASE3SuspendedINTERVENTIONAL
Enrollment

644

Participants

Timeline

Start Date

November 25, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
COVID-19ARDS
Interventions
BIOLOGICAL

SOC plus 15mg/kg EB05 IV

Standard of care plus single IV infusion of 15mg/kg of EB05.

OTHER

SOC plus Placebo IV

Standard of care plus a single IV infusion of placebo.

Trial Locations (20)

33146

University of Miami Hospital, Coral Gables

48202

Wayne State University, Detroit

92835

St. Jude Medical Center/ Providence, Fullerton

93701

UCSF Fresno, Fresno

97213

Providence Portland Medical Center, Portland

01199

Baystate Medical Center, Springfield

26506-6224

West Virginia University Medicine Heart & Vascular Institute, Morgantown

T6G 2B7

University of Alberta Hospital, Edmonton

V5K 1Z9

Vancouver Coastal Health, Vancouver

V5Z 1M9

Vancouver General Hospital, Vancouver

L6R 3J7

William Osler Health System, Brampton

L3P 7P3

Markham Stouffville Hospital, Markham

L3Y 2P9

Southlake Regional Health Centre, Newmarket

L1G 2B9

Lakeridge Health, Oshawa

K1Y 4E9

Ottawa Hospital Research Institute, Ottawa

M5G 2C4

Toronto General Hospital, Toronto

J4V 2H2

CISS Monteregie-Centre, Greenfield Park

H1T 2M4

Hôpital Maisonneuve Rosemont, Montreal

H4A 3J1

McGill University Health Centre, Montreal

G5L 5T1

Hôpital Régional de Rimouski, Rimouski

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

JSS Medical Research Inc.

INDUSTRY

lead

Edesa Biotech Inc.

INDUSTRY